ArticleCancer medicine2021
Prevalence and predictors of peripheral neuropathy after breast cancer treatment.
Article in Cancer medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 3 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Different exercise interventions on quality of sleep in breast cancer survivors-a network meta-analysis of randomized controlled trials.Frontiers in oncology · 2025Pooled it
- Pharmacogenetics of taxane-induced neurotoxicity in breast cancer: Systematic review and meta-analysis.Clinical and translational science · 2022Pooled it
- Incidence and influencing factors of chemotherapy-induced peripheral neuropathy in cancer patients: a systematic review and meta-analysis.Frontiers in neurologyPooled it
- Deferoxamine Improves Radiation-Induced Peripheral Neuropathy.Journal of cellular and molecular medicine · 2026Article
- Educating healthcare professionals on interprofessional counseling in integrative oncology: development and evaluation protocol of the blended-learning program INSIGHT.Frontiers in medicine · 2026Article
- Understanding the Effects of Cancer-Related Factors on the Association Between Physical Activity, Self-Efficacy and Exercise Barriers Among Breast Cancer Survivors.Psycho-oncology · 2025Article
- Optimizing breast cancer chemotherapy by harnessing gut microbiota with insights from artificial intelligence.NPJ biofilms and microbiomes · 2025Review
- Unmet needs among long-term breast cancer survivors.Cancer causes & control : CCC · 2025Article
- Addressing the Needs of Breast Cancer Survivors.Current oncology reports · 2025Review
- Musician's Experience After Breast Cancer Treatment: Defining Musical Toxicity and its Frequency.JCO oncology practice · 2025Article
- Article
- Striding beyond numbness: a non-randomized controlled study of an exercise program for breast cancer patients with chemotherapy-induced peripheral neuropathy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
- Dose delay, dose reduction, and early treatment discontinuation in Black and White women receiving chemotherapy for nonmetastatic breast cancer.The oncologist · 2024Article
- Patient-Reported Outcomes 10 Years After Breast-Conserving Surgery for Early-Stage Breast Cancer.Annals of surgical oncology · 2024Article
- Remote Symptom Alerts and Patient-Reported Outcomes (PROS) in Real-World Breast Cancer Practice: Innovative Data to Derive Symptom Burden and Quality of Life.Bioengineering (Basel, Switzerland) · 2024Article
- A qualitative study of sleep in young breast cancer survivors: "No longer able to sleep through the night".Journal of cancer survivorship : research and practice · 2024Article
- Neurologic Complications in Adult Cancer Survivorship.Seminars in neurology · 2024Article
- Targeting therapy-induced senescence as a novel strategy to combat chemotherapy-induced peripheral neuropathy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Review
- Chemotherapy-induced peripheral neuropathy and its determinants among adult cancer patients on chemotherapy in northwest Ethiopia oncology centers, 2022.Frontiers in oncology · 2024Article
- The Beta2-adrenergic agonist salbutamol synergizes with paclitaxel on cell proliferation and tumor growth in triple negative breast cancer models.Cancer chemotherapy and pharmacology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 9 institutions in 2 countries.
Funding
Abstract
backgroundMany of the 3.8 million breast cancer survivors in the United States experience long-term side effects of cancer therapy including peripheral neuropathy (PN). We assessed the prevalence and predictors of PN among women with breast cancer followed in the Women's Health Initiative's Life and Longevity After Cancer survivorship cohort.
methodsThe study population included 2420 women with local (79%) or regional (21%) stage disease. Presence of PN was based on the reports of "nerve problems and/or tingling sensations" after treatment and PN severity was assessed using the Functional Assessment of Cancer Therapy-Gynecologic Oncology Group/Neurotoxicity instrument. Logistic regression analysis was used to evaluate the socio-demographic and clinical factors associated with PN prevalence and severity.
resultsInitial breast cancer treatment included surgery-only (21%), surgery and radiation (53%), or surgery and chemotherapy (±radiation) (26%). Overall, 17% of women reported PN occurring within days (30%), months (46%), or years (24%) after treatment and 74% reported ongoing symptoms at a median of 6.5 years since diagnosis. PN was reported by a larger proportion of chemotherapy recipients (33%) compared to those who had surgery alone (12%) or surgery+radiation (11%) (p < 0.0001). PN was reported more commonly by women treated with paclitaxel (52%) and docetaxel (39%), versus other chemotherapy (17%) (p < 0.0001). In multivariable analyses, treatment type (chemotherapy vs. none; OR, 95% CI: 3.31, 2.4-4.6), chemotherapy type (taxane vs. no-taxane; 4.74, 3.1-7.3), and taxane type (paclitaxel vs. docetaxel; 1.59, 1.0-2.5) were associated with higher odds of PN.
conclusionPN is an important long-term consequence of taxane-based chemotherapy in breast cancer survivors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.